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The introduction of comprehensive testing techniques, such as microarray technology or whole genome
sequencing, in embryo testing has the potential to change the practice of Preimplantation Genetic
Diagnosis (PGD) and Preimplantation Genetic Screening (PGS). However, the extra information these
procedures yield may potentially generate dilemmas for couples and professionals regarding the scope of
the tests and the selection of the right embryo. In order to understand this complexity and reflect on its
consequences, we organized two expert panels consisting of professionals working in the field of assisted
reproduction and/or genetics. We found that there is great uncertainty amongst professionals how to
tackle questions related to comprehensive screening, such as which conditions to test for and who
should have the final say on which embryo to select, and a lack of a framework from which such
questions can be answered. Moreover, the complexity of genetic information comprehensive tests may
yield may make it impossible to select the best embryo altogether.
 2012 Elsevier Masson SAS. All rights reserved.1. Introduction
The removal of a blastomere from 3-days old in vitro embryos
for preimplantation genetic diagnosis (PGD) was first developed to
help couples with a known risk of transferring a severe genetic
mutation to their offspring. The diagnosis of the embryo is done
using the PCR technique (Polymerase Chain Reaction) or FISH
(Fluorescent in situ hybridization), and based on the outcome of the
test, an unaffected embryo would possibly be transferred. An
unaffected embryo in this context is either an embryo without the
specific genetic mutation or, in case of X linked diseases, a female
embryo. The target patients for this procedure are mostly fertile
couples with a known genetic mutation in their family. Later, FISH,
was also introduced to screen embryos from infertile or subfertile
couples undergoing IVF as fertility treatment. This preimplantation
genetic screening (PGS) aims to increase the chance of a successful
pregnancy by means of selecting euploid embryos. However, PGS, Faculty of Health, Medicine
he Netherlands. Tel.: þ32 (0)
. Hens).
on SAS. All rights reserved.with FISH is now contested, as several clinical trials have shown
that it does not fulfill this aim. A possible reason for this is that with
FISH not all chromosomal abnormalities are detected, as with FISH
only a subset of chromosomes can be tested. Moreover, the biopsied
blastomere may not be representative of the entire embryo,
a phenomenon known as mosaicism [1e3].
Microarray technology such as CGH-arrays and SNP arrays are
gradually being introduced in the IVF clinic [4e8]. It is now also
technically possible to use whole genome sequencing on a single
blastomere: hence, this technique may be applied in a clinical
context in a not so distant future. Such comprehensive screening
techniques can be applied both in the context for PGD and PGS. In
the former case, they have the advantage of offering off the shelf
tests without the need of extensive customization. In the latter
case, they allow for the screening of most, if not all, chromosomes
at the same time. Therefore, the use of microarrays may eliminate
some of the current issues related to PGS, as it provides compre-
hensive information about the chromosomes and hence more
accurate information about possible aneuploidies [9]. An additional
advantage of the introduction of these techniques is that next to the
original aim of the procedure (to avoid transfer of a genetic
mutation in case of PGD or to enhance pregnancy rates by screening
for aneuploidy in case of PGS), extra information becomes available
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tional information these procedures yield may however potentially
generate dilemmas for couples and professionals regarding the
scope of the tests and the selection of the right embryo.
Julian Savulescu framed the principle of procreative benefi-
cence, stating that whenever doing so is reasonably possible, all
relevant information needs to be taken into account to allow for the
selection of the embryo with the best possible outlook in life
[10,11]. In his account this duty seems primarily cast upon the
couple undergoing the procedure. However, in a paper issued by
the ESHRE task force on Ethics and Law, it is stated that the
physician carries joint responsibility for the welfare of the child
because of his or her causal and intentional contribution to the
parental project [12]. Also Draper and Chadwick [13] have stated
that PGD shifts the power from the woman to the physician, as the
latter has the ultimate say in the transfer of the embryo. And de
Wert [14] and Pennings et al. [15] have argued, in the traditional
context of PGD and assisted reproduction, that professionals as
collaborators in the parental project of the couple have their
responsibilities regarding the outcome and can set conditions on
their participation. However, with the abundance of information
microarrays and next generation sequencing may yield, the roles of
the couple and professional in choosing the best embryo to transfer
becomemore andmore complex. Therefore, in order to understand
this complexity and reflect on its consequences, we organized two
expert panels consisting of professionals working in the field of
assisted reproduction and/or genetics. The remainder of this paper
describes the methods and results of this expert panel study and
a discussion of the implications. In Table 1 we give an overview of
the existing techniques. Screening in the context of embryo selec-
tion has a specific meaning as it refers to the screening of embryos
for aneuploidies in the context of fertility treatment, to enhance
pregnancy rates. In this paper we shall use the term comprehensive
embryo testing as an umbrella term for both comprehensive PGS
and PGD.
2. Materials and methods
We conducted two expert panels to investigate the opinions and
concerns of professionals working in the field of assisted repro-
duction and genetics with regard to the introduction of compre-
hensive embryo testing in the clinic. One expert panel was held in
Leuven, Belgium and consisted of five participants from Belgium
and one from the Netherlands. Two of them were fertility doctors,
three were clinical geneticists and one was a PGD scientist. The
other expert panel was held in Utrecht, the Netherlands. In this
group we had also six participants, of which one was an embryol-
ogist, one was a fertility doctor and four were clinical geneticists.
The expert panels were conducted with WD as a moderator. KH
was observer. At the beginning of each discussion, the participants
were told that the talk was audio taped andmay be published. They
were assured that this report would contain only anonymous data.
The participants were presented with different possibleTable 1
Overview of techniques and applications.
Technique Target audience Aim
PGD with FISH/PCR Fertile and infertile couples at risk for transferring genetic
disease or chromosomal translocation
Avo
(in
Comprehensive PGD Fertile and infertile couples at risk for transferring genetic




PGS with FISH Infertile couples Enh
Comprehensive PGS Infertile couples Firs
bettapplications of comprehensive testing. The first application con-
sisted of the inclusion of aneuploidy screening in PGD, next to
testing for the known genetic mutation of chromosomal trans-
location. The second possible application dealt with the inclusion of
testing for Mendelian diseases in PGS and for Mendelian diseases
beyond the original medical indication in PGD. Thirdly, they were
presented with the possibility to also screen for risk factors and
genetic susceptibilities, both in the context of PGD and PGS. And
fourth, they were asked to consider the possibility of including non
medical traits as selection criteria.
Audiotapes of the sessions were transcribed but not corrected
for grammar, in order to capture the oral nature of the discussion.
Selected quotes were translated in English during the write-up of
this paper. We used NVIVO 9 to do a detailed coding of the tran-
scripts. The results of the coding were compared by KH, WD and
GDW. In this paper, all participants are referred to by ‘she’ and ‘her’,
regardless of their gender.
3. Results
We expected to find a strong emphasis on the responsibility of
the professional towards the welfare of the future child, but found
this emphasis primarily in the case of embryos with trisomy-21.
Instead, we found respect for the autonomy of the couple but
also an uncertainty as to how to convey complex information, and
an expressed need for proper reflection on the issue at hand.
3.1. Testing for aneuploidies
A relatively straightforward application of comprehensive
screening of embryos is screening for aneuploidies. Indeed, the use
of microarray technology for embryo testing can reveal information
about the chromosomal status of the embryo. This can be done both
in the context of IVF treatment of infertile couples (PGS), or in the
context of PGD, where next to testing embryos for specific muta-
tions, they can also be screened for aneuploidy or where testing for
chromosomal abnormalities resulting from known chromosomal
translocations can also reveal unrelated aneuploidies. Whereas
many forms of aneuploidy are incompatible with life, some are
compatible, trisomy-21 being the best known case. It was agreed
almost unanimously that trisomy-21 embryos would not be
transferred, even if the couple requested the transfer. Reasons given
were the idea that professionals would not want to willingly
contribute to bring into existence a handicapped child, as is clear
from the following quote:
I do not think so, in the context as we have it now, because that
would meanwe are potentially creating a child with trisomy-21,
and we do not want to do that.
It was stated, however, that the embryo was still the property of
the couple and they could claim it in order to take it to another
centre. One participant made a distinction between embryos that
were actively tested for chromosomal abnormalities in the contextid transfer of a genetic mutation. Enhance chance of a successful pregnancy
case of chromosomal translocations)
t aim: avoid transfer of specific mutations or translocations. Possible additional
s: selecting children with better health profiles. Selecting children with the best
sible outlook in life
ance pregnancy rates
t aim: enhance pregnancy rates. Possible additional aims: selecting children with
er health profiles. Selecting children with the best possible outlook in life
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latter case, the chromosomal abnormality was not the aim of the
test and she could understand that in such cases you would
consider a transfer. All agreed that such scenarios would have to be
talked through with couples before the cycles were started, during
counselling sessions. It was stated that if, at that point, the couple
would make clear that they would want to have an embryo with
trisomy-21 transferred, this should not be tested for in the first
place. Interestingly, participants seemed to imply here that the
professional responsibility not to create a handicapped or severely
limited life only applied to known conditions in the embryo, after
testing. It does not imply any further duty to test all embryos for
that condition, and couples can choose not to test for these
conditions at all.
3.2. Adding more tests: zooming in on the genes
During the discussion on chromosomal abnormalities it was
strongly suggested that doctors should not knowingly contribute to
bringing into existence a child with a severe handicap. However, it
was unclear whether this was considered a duty towards thewelfare
of the future child or a means of protecting the parents frommaking
a choice they would regret afterwards. Indeed, throughout the
discussion, participants thought the consideration that clinicians
would have major responsibility to the welfare of the future child
due to their involvement not decisive. One participant asked:
But are you doing that because of your own responsibility
towards the child or because of thewishes of the parents to have
a child that is as healthy as possible?
Hence, she suggests that the responsibility in this field might be
primarily towards the couple. Another participant clearly disagreed
with the stance that a fertility doctor had any duty other than
helping infertile couples have a baby.
Microarray technology and, in the future, single cell whole
genome sequencing would allow for the screening for a vast range
of Mendelian diseases. This could be done in the case of PGS,
possibly as an add-on to aneuploidy screening, or in the case of
PGD, as an additional screening on top of the genetic condition to
be tested for. However, participants were unsure whether the
extension of the testing to the detection of genetic mutations
leading to such conditions would yield useful information for
selection. Although participants admitted that this could yield
information that would possibly allow selecting an embryo leading
to a healthy child, they also stated that the decision of which
disease would be included in the test would be difficult. Moreover,
many of these diseases occur only infrequently and there was
uncertainty whether the benefit of including such infrequent
conditions in the testing would weigh up against the additional
difficulty of counselling couples about many more diseases. Indeed,
participants stated that there was a responsibility of the doctor to
help couples make well informed decisions. However, given the
complexity of comprehensive genetic information, patients should
not be overburdened with information, as this would make their
decision making too complex if not impossible. Especially with
regard to the hypothetical scenario in which the testing range was
extended to the entire genome and included also genetic suscep-
tibilities and risk factors, there was great doubt whether this ideal
of the professional allowing couples to make their own reproduc-
tive choices was achievable:
But if they have to decide this. because it is that what you are
saying, I have a disposition for this and what shall we do next.
For 50% of the couples I encounter, this is not feasible. They will
not be able to understand it.The participant here explicitly states that it is up to the couple to
decide based on the available genetic information. However, she
also acknowledges that such decision making would be almost
impossible for many couples, as they would lack the knowledge, or
even the intellectual capacity to grasp such complex information.
Indeed, the lack of knowledge about the predictive value and
risk factors was quoted as a major issue for the introduction of
comprehensive screening techniques per se, also regardless of the
capacity of the couple to understand the technology and make the
right choices. In principle, sufficient genetic knowledge should
allow the setup of risk profiles for embryos to allow for better
selection. However, given the complexity of the matter it was
uncertain whether this would ever be possible.
I think, recombination, spontaneous mutation and different
factors contribute, so you could say. But anyway maybe those
people do not even suffer from it. Maybe that male patient of 35,
coming for IVF, has a predisposition for prostate cancer when he
is 60. But anyway, he does not now it, he has those genes, but it
is possible that they are never expressed. I mean, you could
make a ranking but that ranking will be enormous.
Astronomical.
In this quote, the participant expresses her concerns about the
possibility of ever making correct predictions based on genotype
alone.
3.3. Broadening the testing scope
Some time was spent discussing the potential societal implica-
tions of broadening the scope of embryo testing to include further
health factors. On the one hand, participants suggested that
selecting only healthy embryos would have an economical impli-
cation, as this would save costs for the public health system. If such
selection could be done safely without losing sight of the primary
aim of couples (to have a child), the term duty was used.
I think indeed if there is enough proof that this technology is
necessary, meaning the cost benefit analysis and all that stuff. If
there is real proof that it is better for the patient, the children
and society and everybody, then there is indeed a duty to do it.
And a duty from the government to pay for it.
In this context, Participants did not see a major conflict between
public health concerns and wishes of the parents. Indeed, it was
stated that the main aim of couples in reproduction is having
a healthy child.
On the other hand, therewas fear that therewould be additional
cost reductions and reimbursement limits in the IVF clinic, making
the introduction of more comprehensive tests unlikely. There was
uncertainty about whether such options could be offered to people
wanting to pay for themselves. It was thought that the group
willing to pay to have a better selection of embryos would be fairly
limited. A reason for this was that the aim of couples to have
a maximally healthy child was considered subordinate to their
primary aim, to have a child altogether.
Especially when discussing the possibility of also considering
non-health related traits in the selection participants expressed
unease and uncertainty. Participants quoted the possibility of
selecting on the basis of the sex of an embryo as an example of how
this was already today an issue. One participant stated that having
the law forbidding sex selectionwas a benefit, and should selection
based on non-health related traits become possible, there was
certainly a need for reflection and guidance. However, there was
a disagreement whether such guidance should come in the form of
laws, or whether guidance would primarily be done through self
regulation and guidelines by professional organizations. One
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bodies should supplement the individual decision making of the
professional, as she feared that individuals would have conflicting
interests:
I do not agree with that, the responsibility of the doctors do not
overestimate that. A doctor thinks in his own interest, a doctor
wants to make a nice website with nice results to entice people
to come. Many doctors are not really occupied with the health of
the offspring. Sometimes boards have to intervene to say, this
can no longer be done.
In this quote she expresses her fear that many professionals
would be led by a desire to make money, rather than considering
the welfare of the child.
4. Discussion
The principle of procreative beneficence as framed by Julian
Savulescu in the context of embryo selection states that prospective
parents have a moral obligation to select those embryos for transfer
with, all things considered, the best outlook in life [10,11,16]. Until
recently, embryo testing was limited to the diagnosis of aneuploidy
or a specific genetic defect, in which cases selection was relatively
straightforward and limited to those conditions. However, with the
introduction of comprehensive screening techniques, the principle
of procreative beneficence seems to have become self-evident:
Indeed, as more information becomes available about the embryos
to be selected, it appears to be the right thing to do to choose the one
with the best outlook in life, based on specific health traits, or even
more, also on the basis of non-health related characteristics such as
intelligence or memory capacity, an option which is today still
technically impossible. But our expert panel study has demon-
strated that the introduction of these techniques also introduces
many questions, and that the assumption that themore information
that is available the better selection can be made is naïve.
The questions raised by the introduction of these techniques are
to be found on different levels. The first level is the contrast
between PGD and PGS, technically similar procedures but with
different aims. For PGD the primary aim of most couples is to have
a child not affected by a specific genetic disease or a chromosomal
translocation. PGS is done in the context of assisted reproduction in
infertile couples, to select the embryo with the best chance of
leading to a successful pregnancy. Secondly, unlike natural
conception, in the context of IVF and PGD/PGS at least three parties
are affected by the conception: the couple, the clinician and the
future child. And thirdly, responsibilities may be different at
different stages of the procedure. Beforehand, there is the question
of which tests should be offered to whom, and who can decide on
which conditions or characteristics to test for. After testing, there is
the question of who gets the final say in which embryo to select for
transfer.
4.1. The role of the physician
In our study we found that the introduction of comprehensive
embryo screening introduces additional unclarity about the role of
the physician. Ethical literature suggests that the clinician involved
in the procedure has some responsibility towards thewelfare of the
future child, and hence should also have a say about the fate of
specific embryos [14,15]. And although also in the traditional
context of PGD with FISH or PCR and PGS with FISH conflicts could
arise and couples might request affected embryos to be transferred,
the situationwas clear cut in most cases. The main reason for this is
that outcome was directly related to the original aim of the
procedure: to enhance implantation and pregnancy rates (for PGS)or to avoid the transfer of a genetic disease (for PGD), and is
consistent with official guidelines from ESHRE not to transfer an
affected embryo. As such, it is also an example of the principle of
procreative beneficence.
This traditional approach to embryo testing was resonated in
our expert panels in the viewpoints on transferring an embryowith
trisomy-21, which was in general thought to be unacceptable. An
explanation for this could be the underlying assumption that
trisomy-21 is also linked to a lesser chance of implantation and
enhanced rate of miscarriages [17], and is therefore directly linked
to the original aim of the procedure. Remarkably, however, this
duty not to transfer an embryo with trisomy-21, after testing, was
not directly analogous to a duty to offer a test for this condition (as
an IVF professional) or to accept testing for the condition (as an
infertile couple), even when this extra information would be made
available without extra costs, burdens or additional procedures.
Indeed, respondents thought that couples could still choose not to
know about the chromosomal status of the embryo if they had no
problems if also chromosomally abnormal embryos were trans-
ferred. This is analogous to the prenatal context, where no woman
can be forced to undergo prenatal screening of trisomy-21. Indeed,
the offer of a prenatal test to a pregnant woman should be without
any obligations and the counselling before and after the test should
be non-directive [18]. It is remarkable that the same dynamics also
seem to apply to the preimplantation case, where there is a more
active involvement of the clinician, an involvement that is consid-
ered by the literature as ethically relevant. One could indeed argue
that the duty of non-directiveness is far less obvious in the
preimplantation context, where there is no termination of preg-
nancy, only information leading to selecting the better embryo.
However, our participants did not have the immediate reflex to
advocate additional testing. Remarkably also, it was thought that,
although physicians could refuse to transfer an embryo with
trisomy-21, the embryo was still thought of as belonging to the
couple. Hence, the couple would have the right to take the embryo
to another centre for transfer. This raises the question whether
there is a duty of the physician to contact other centers or whether
there should be a cross country policy on how to deal with such
results. However, our participants did not consider these issues.
4.2. Impossible choices
As soon as the focus of the discussion was shifted to adding also
Mendelian diseases and risk factors to the selection, the apprecia-
tion of the usefulness (though not the obligation) of additional tests
was far less prevalent, although participants acknowledged the
potential of extending testing also to such diseases. On the one
hand, respondents thought of themselves as primarily having the
role of facilitators of choices. Couples should be adequately coun-
selled about possible outcomes of tested, but the primary decision
power lay ultimately with the couple. On the other hand, it was also
suggested that given the complexity of the possible outcomes of the
tests, choices would be almost impossible to make. The complexity
of the information was beyond the average capabilities of most
couples, and this was seen as a reason not to introduce these tests.
However, people considered this a shortcoming of the introduction
of comprehensive techniques itself, not as a reason to rethink the
roles of patients and clinicians. Indeed, it was never suggested that
because of the complexity of the matter decisions about selection
should be entirely left to the physician.
4.3. A clash of aims
Couples being offered embryo testing do so because they have
specific aims. In the case of PGS they want to enhance the chance of
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transfer of a genetic disease to their child. If comprehensive
screening techniques are introduced in the IVF clinic, additional
aims may be achieved. Embryos can be selected based on health
profiles, or, when genetic knowledge advances evenmore, based on
non-health related traits which are nonetheless welfare related.
However, there is always a limited amount of embryos to select
from. Moreover, it may be impossible for the woman to undergo
another IVF cycle, either due to physical reasons or because it is too
expensive. What then to do if all embryos carry certain mutations,
or if the testing itself has failed? To allow too many factors to enter
the equation, might make selection impossible and might lead to
the fact that the original aim, of having a child, becomes neglected.
Maybe principles of selection and of non transfer of affected
embryos should be relaxed if the primary aim becomes more
difficult to attain, for example because all embryos carry mutations
that are risk factors for certain conditions, or because the only
embryo available for transfer has a milder chromosomal defect
such as Klinefelter. Also, the offer of more comprehensive precon-
ception genetic tests could to some extend already prepare couples
for what they might expect, and give them more time to consider
alternative ways of reproduction.
We acknowledge that our study has several limitations. Given
the limited number of participants (twelve in total) our study can
only hint at what professionals find important with regard to the
introduction of comprehensive testing techniques in the practice of
PGD or PGS. Also, the voluntary nature of expert panel participation
may imply that the participants might have been biased, either in
the positive or the negative sense.
We found that there is great uncertainty amongst professionals
how to tackle questions related to comprehensive screening, such
as which conditions to test for and who should have the final say on
which embryo to select, and a lack of a framework fromwhich such
questions can be answered. Moreover, given the complexity of the
genetic information, the principle of procreative beneficence is
perhaps difficult to apply in a straightforward way. Hence, there is
a need for timely reflection on the different roles of all stakeholders
and for the development of a general framework that can function
as a baseline to support individual choices of patients and
caregivers.
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